The stock of Apogee Therapeutics Inc (NASDAQ: APGE) has increased by 0.14% when compared to last closing price of $44.26.Despite this, the company has seen a gain of 3.09% in its stock price over the last five trading days. zacks.com reported 2025-06-09 that The average of price targets set by Wall Street analysts indicates a potential upside of 129.1% in Apogee Therapeutics Inc. (APGE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Is It Worth Investing in Apogee Therapeutics Inc (NASDAQ: APGE) Right Now?
APGE has 36-month beta value of 1.49. Analysts have mixed views on the stock, with 9 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for APGE is 37.32M, and currently, short sellers hold a 24.59% ratio of that float. The average trading volume of APGE on July 03, 2025 was 738.15K shares.
APGE’s Market Performance
APGE stock saw an increase of 3.09% in the past week, with a monthly gain of 21.99% and a quarterly increase of 24.46%. The volatility ratio for the week is 4.64%, and the volatility levels for the last 30 days are 6.00% for Apogee Therapeutics Inc (APGE). The simple moving average for the last 20 days is 5.45% for APGE’s stock, with a simple moving average of 1.89% for the last 200 days.
Analysts’ Opinion of APGE
Many brokerage firms have already submitted their reports for APGE stocks, with Citigroup repeating the rating for APGE by listing it as a “Buy.” The predicted price for APGE in the upcoming period, according to Citigroup is $95 based on the research report published on March 13, 2025 of the current year 2025.
Canaccord Genuity, on the other hand, stated in their research note that they expect to see APGE reach a price target of $89. The rating they have provided for APGE stocks is “Buy” according to the report published on November 25th, 2024.
BofA Securities gave a rating of “Buy” to APGE, setting the target price at $80 in the report published on May 10th of the previous year.
APGE Trading at 11.49% from the 50-Day Moving Average
After a stumble in the market that brought APGE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -30.20% of loss for the given period.
Insider Trading
Dambkowski Carl, the Chief Medical Officer of Apogee Therapeutics Inc, sale 2,725 shares at $36.96 during a trade that took place back on Jun 04 ’25, which means that Dambkowski Carl is holding 241,723 shares at $100,716 based on the most recent closing price.
Stock Fundamentals for APGE
The total capital return value is set at -0.35. Equity return is now at value -27.85, with -26.71 for asset returns.
Based on Apogee Therapeutics Inc (APGE), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -15.91.
Currently, EBITDA for the company is -216.87 million with net debt to EBITDA at 0.39. The liquidity ratio also appears to be rather interesting for investors as it stands at 15.82.
Conclusion
To put it simply, Apogee Therapeutics Inc (APGE) has had a better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
